"Stocks are likely in a new downtrend," says Michael Ashbaugh. In Marketwatch's The Technical Indicator, he looks at the S&P's prospects and some drug stocks set to buck the trend.

"The S&P 500 has violated its major moving averages in the closely tracked 900 area. The recent downturn was convincingly bearish, placing the burden on market bulls to reassert the uptrend.

"After finding resistance in the 923 area, the S&P sold off sharply, edging back under its 200-day moving average, which currently holds at 900 and now marks resistance. This is bearish price action.

Surviving this recession is foremost on peoples' minds, but giving to charity is especially important in times like these. So how can you effectively give while preserving your net worth?

If you plan on liquidating any profitable, or taxable, positions in the stock market thanks to the current uptrend and also want to give to your favorite charity, the strategy outlined below is key to optimizing your gift, as well as your capital.

Though giving cash to causes is the most popular form of charity, desperate times call for creative measures, and any type of gift will be gladly accepted. By giving stock directly to charity, and bear in mind that the stock must be in your portfolio for one year or more as short-term capital gains are not applicable, you not only avoid capital gains taxes on your gains, but you can actually use the gift of your stock as a tax deduction. Hence, the cost of your gift is lower than giving cash directly. Think of it as an overall investment for yourself and the charity.

"Generic drug mak Teva Pharmaceutical, Ltd. (NASDAQ: TEVA) delivered respectable earnings results," says Jack Adamo, who added the stock his Insiders Plus model portfolio.

"The company's earnings were up 4% on a proforma non-GAAP basis. In this case, that's the correct measurement. Net GAAP earnings were up tremendously, but aren't really representative of normal business factors.

"Although Teva gets much of its earnings from its proprietary multiple sclerosis drug, Copaxone, its primary business is generic drugs. That segment is inherently lumpy because profitability is greatly affected by which generic drugs it brings to market before any other generic company.

Here are some highlights from this past week's earnings coverage from BloggingStocks:

• Alcatel-Lucent (NYSE: ALU) shares rose even though it reported a wider loss for the quarter.
• American Express Co. (NYSE: AXP) posted better-than-expected Q1 results but warned of challenges.
• Blackstone Group (NYSE: BX) reported a net loss and slumping revenues for the first quarter.
• Center Financial Corp. (NASDAQ: CLFC) was downgraded following its Q1 earnings report.
• Cisco Systems Inc. (NASDAQ: CSCO) posted lower Q3 earnings that still topped analysts estimates.

Here are some highlights from this past week's earnings coverage from BloggingStocks:

• Activision Blizzard Inc. (NASDAQ: ATVI) Q1 results beat expectations and raised its guidance.
• Alpha Natural Resources Inc. (NYSE: ANR) shares surged after the it reported strong Q1 earnings.
• Archer Daniels Midland Co. (NYSE: ADM) just missed swinging to a loss due to to hefty investment losses.
• CBS Corp. (NYSE: CBS) surprised with a net loss in Q1 as revenue and cash flow declined.
• Chesapeake Energy Corp. (NYSE: CHK) shares fell after it reported disappointing results for the quarter.

Analyst upgrades:

• Jefferies upgraded Brocade (NASDAQ: BRCD) to Buy from Hold on expectations expanding OEM partnerships, new products and entry into new markets will drive long-term growth. The firm's channel checks indicate the first phase of an IBM (NYSE: IBM) deal for ethernet products will be announced next week. Jefferies raised its target price on the stock to $6 from $3.50.
  
• JMP Securities upgraded Broadcom (NASDAQ: BRCM) to Market Perform from Underperform citing the potential settlement with Qualcomm (NASDAQ: QCOM). The firm said Broadcom has far more to gain than Qualcomm has to lose.
  
• Citigroup upgraded Air Products (NYSE: APD) and Praxair (NYSE: PX) to Buy from Hold on expectations that an improvement in customer operating rates will benefit gas companies. The firm raised its target price on Air Products to $70 from $55 and on Praxair to $79 from $63.
  
• Royal Bank of Scotland upgraded BP Plc (NYSE: BP) to Buy from Hold to reflect its dividend yield at current levels.
• Apple (NASDAQ: AAPL) was raised to Outperform from Underperform at RBC Capital.
  
• T. Rowe Price (NYSE: TROW) was upgraded at Sandler O'Neill to Hold from Sell.
  
• Morgan Stanley (NYSE: MS) was lifted to Neutral from Underperform at Banc of America/Merrill.

Analyst upgrades:

• Bernstein upgraded Merck (NYSE: MRK) to Outperform from Market Perform and raised its target to $30 from $27 citing valuation and its decision to buy Schering-Plough, at what appears to be a reasonable price.
  
• RBC Capital upgraded Palm (NASDAQ: PALM) to Outperform from Sector Perform and raised its target to $12 from $5 as it believes webOS has increased its chances for Smartphone leadership and will increase its attractiveness as an acquisition target.
  
• RW Baird upgraded Alcatel-Lucent (NYSE: ALU) to Outperform from Neutral on valuation as it believes balance sheet risks are overly discounted in the stock, creating a buying opportunity. The firm has a $3 target on shares.
• Express Scripts (NASDAQ: ESRX) was raised to Buy from Hold at Argus.
  
• France Telecom (NYSE: FTE) was upgraded at Morgan Stanley to Equal Weight from Underweight.
  
• Foster Wheeler (NASDAQ: FWLT) was upgraded to Conviction Buy from Neutral at Goldman.

Here are some highlights from this past week's earnings coverage from BloggingStocks:

• Apollo Group Inc. (NASDAQ: APOL) reported that Q4 revenue soared despite the recession.
• Baidu Inc. (NASDAQ: BIDU) posted strong annual revenue, but at a slowing growth rate.
• Career Education Corp. (NASDAQ: CECO) easily topped Q4 earnings expectations, lifting shares up.
• Comcast Corp. (NASDAQ: CMCSA) Q4 earnings beat expectations and it increased its dividend.
• CVS Caremark Corp. (NYSE: CVS) shares jumped after it reported higher earnings in Q4.
• Digital River Inc. (NASDAQ: DRIV) shares soared on better-than-expected Q4 earnings and revenue.
• Expedia Inc. (NASDAQ: EXPE) reported dismal results due to a huge good will write down.
• Goodyear Tire & Rubber Co. (NYSE: GT) posted a greater-than-expected Q4 net loss and announced job cuts.
• Hormel Foods Corp. (NYSE: HRL) exceeded Q1 earnings expectations due to the popularity of SPAM.

U.S. stock markets were set to plunge at the open Tuesday morning as three issues weighed on investors' minds: The economic stimulus plan, the auto industry as well as hard-hit Eastern Europe: Before the bell: Stocks set to plunge on stimulus package, auto sector worries

General Motors Corp. (NYSE: GM) and Chrysler LLC are expected to submit recovery plans to the government today to show how they can repay billions in loans and become viable. Of course, abysmal auto sales haven't been helping any company in the industry. Ex-Lazard banker Ron Bloom is expected to be named a key government adviser, according to The Wall Street Journal, and he is expected to be tough, demanding sacrifices by all involved, from auto workers and industry executives to shareholders and creditors. The AP reports that GM was making progress in concession talks with debtholders and the UAW. Also, GM Europe is considering shutting or selling as many as four European plants. GM shares are down 5.6% in premarket trading. GM shares declined over 12% an hour after the open.

One stock that I think has traded irrationally is Deckers Outdoor Corp. (NASDAQ: DECK).

Shares of the UGG and Teva footwear company had fallen to $80 per share in late October, but lost nearly 50% of its value from there in November.

Considering that the company increased guidance on Oct. 23, this move made little sense.

When I last wrote about DECK in July, shares were trading for more than $100, but well off their highs above $160. At that time, I suggested that investors resist the urge to buy the beaten-down stock, no matter how tempting.

It wasn't that I didn't believe in the potential of the company. Instead, the macro picture being as it was at that time suggested waiting for a better entry point. I thought below $80 would make sense.

I was right about waiting, although I did not think the stock would sink to less than $50 as it did in late November. Obviously something was amiss given that DECK's performance was quite stellar.

Analyst upgrades:

• UBS upgraded Kansas City Southern (NYSE:KSU) to Buy from Neutral and lowered its target to $26 from $35 citing valuation.
  
• Gabelli upgraded Media General (NYSE:MEG) to Hold from Sell because the firm thinks that Harbinger Capital has sold most of its shares in the company. As a result, the firm thinks the stock will be under less selling pressure.
  
• Eagle Bulk Shipping (NASDAQ:EGLE) was upgraded to Neutral from Underperform at Merrill Lynch.
• Centene (NYSE:CNC) was raised to Buy from Neutral at Goldman.
  
• Ralcorp (NYSE:RAH) was upgraded at Credit Suisse to Outperform from Neutral.
  
• Interpublic Group (NYSE:IPG) was upgraded to Equal Weight from Underweight at Morgan Stanley.

Analyst downgrades:

• Keefe Bruyette downgraded Healthcare Realty(NYSE:HR) to Market Perform from Outperform on concerns the company's development activity could be dilutive to near-term earnings.
  
• Citigroup downgraded Satyam (NYSE:SAY) to Sell from Buy as they believe the company's acquisition plans, and subsequent cancellation of the deals, will lessen investor confidence in the name.
  
• Oppenheimer downgraded Apple (NASDAQ:AAPL) to Perform from Outperform citing Steve Jobs cancellation of his annual key note speech at Macworld on January 6. The analyst said the unexpected announcement underscores Apple's long-term dependence on Job's health and its lack of succession plan.
• Baird downgraded Carlisle NYSE:CSL)to Neutral from Outperform.
  
• Gibraltar Industries (NASDAQ:ROCK) was downgraded at Piper Jaffray to Sell from Buy.
  
• NetApp (NASDAQ:NTAP) was cut to Accumulate from Buy at ThinkPanmure.

Analyst initiations:

• Citigroup believes the acquisition of Barr enhances Teva's (NASDAQ:TEVA) growth. The firm started shares with a Buy rating and $52 target.
  
• Suntrust initiated American Express (NYSE:AXP) with a Reduce citing slowing growth and greater-than-industry deterioration in credit quality.
  
• Roth Capital initiated The Buckle (NYSE:BKE) with a Hold rating and $17 target citing the deteriorating macro environment.
• Amazon.com (NASDAQ:AMZN) and Allegheny Tech (NYSE:ATI) were assumed with Neutral ratings and targets of $52 and $26, respectively, at UBS.
  
• Digital Realty (NYSE:DLR) was initiated at Piper Jaffray with a Buy rating.
  
• Mylan (NYSE:MYL) was started with an Overweight rating and $15 target at JP Morgan.

Teva Pharmaceuticals (NASDAQ: TEVA - option chain) shares have moved higher today after the Food & Drug Administration approved the company's generic version Pulmicort, an asthma drug made by competitor AstraZeneca (NYSE: AZN). If you think that the stock won't fall by too much in the coming months, then now could be a good time to look at a bullish hedged trade on TEVA.

TEVA opened this morning at $43.00. So far today the stock has hit a low of $42.55 and a high of $43.78. As of 12:25, TEVA is trading at $42.84, up $0.65 (1.5%). The chart for TEVA looks bullish and S&P gives TEVA a positive 5 STARS (out of 5) strong buy ranking.

For a bullish hedged play on this stock, I would consider a January bull-put credit spread below the $35 range.

Analyst upgrades:

• Goldman upgraded Bed Bath & Beyond (NASDAQ: BBBY) to Buy from Neutral based on valuation and a potential margin rebound at Linens N' Things.
  
• Citigroup upgraded Rockwell Automation Inc. (NYSE: ROK) to Hold from Sell on valuation and believes expectations have been reset to a reasonable level. The company's target was lowered to $27 from $33.
  
• Friedman Billings upgraded shares of Ceradyne (NASDAQ: CRDN) to Outperform from Market Perform on valuation following the recent weakness and thinks the Army will move forward with a larger XSAPI procurement in FY09. The firm raised their target to $30 from $26.
• Goldman added Wyeth (NYSE: WYE) to the Conviction Buy List.
  
• Equity Residential (NYSE: EQR) was upgraded to Buy from Neutral at UBS.
  
• Analog Devices (NYSE: ADI) was raised to Overweight from Equal Weight at Morgan Stanley.

Analyst downgrades:

My colleague (sort of) James Cramer has suddenly turned into a giant, growling bear. He has been moving in that direction for a few months and now he thinks we all should go into hibernation for five years. He is so wrong!

First of all, it is never a good idea to make decisions while you are in panic mode. Second, Jim's guidance is moving with the market so he is not making any serious prognostication, just staying slightly ahead of the mob. He might as well stick his finger in the air.

Are things bad? Yes! Could they get worse? Yes! Would I run for the hills? ABSOLUTELY NOT! Even though I agree we are in for some tough times, I think the market is reacting to more than meets the eye (see All bets are off -- stocks' irrational downside).

If I recall correctly, 50% of the significant gains in the Dow Jones Industrial Average were made on 7% of the up days. You have to be in the game to win the game. If you are in panic mode you should alter your investment portfolio so that you can rest easy. Diversification helps and speculation hurts.

Most people who have been investing for any length of time have heard of dollar cost averaging. This is where you put a certain amount of money into an index fund regularly each month, so that when the market is up you are buying fewer shares at higher prices and when the market is on sale, like it may be today, you are buying more shares at a lower price. This allows you to grow your portfolio consistently while paying a reasonable price for the shares you add -- on average.

It was July 1, 2008 when I first posted Serious Money: Five stable stocks for troubled times. The title speaks for itself. This update, after nine weeks and horrible market conditions, is through Friday October 3, 2008.

The index for comparison is the Standard & Poor's 500 Index, which closed on June 30, 2008 at 1,280.00. The S&P closed Friday at 1,099.23 , down 14.12%.

Each of my five picks is beating the market and three of the five are actually up despite crushing news in the financial sector, unemployment and housing. Congress did pass a Wall Street backstop/bailout bill that President Bush has signed, but only after adding another 450 pages and $130 billion to the amount. Although the five stocks have averaged a 0.75% loss, as intended, they easily beat the S&P by 13.37%.

Here are the five stocks that I still think are worth considering. For my original rationale see the linked story above.

1) Johnson and Johnson (NYSE: JNJ) -- when recommended, the stock closed at $64.34 and paid a 2.89% dividend yield. It closed Friday at $66.16 -- up 2.75%. JNJ was featured in Barron's this month as the most respected from the top 100 companies in the world.

2) Teva Pharmaceuticals ADR (NASDAQ: TEVA) -- when recommended, the stock closed at $45.80 and paid a 1% dividend yield. It closed October 3 at $46.08 -- up 0.06% 0.62% Teva (of Isreal) is the largest generic drug company in the world and just got bigger through the acquisition of Barr Pharmaceuticals last month.